PriceTargets.com logo

ImmunoPrecise Antibodies - IPA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.00
  • Forecasted Upside: 183.69%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.82 As of 03/30/2023 01:00 AM ET
▲ +0.02 (0.71%)

This chart shows the closing price for IPA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImmunoPrecise Antibodies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPA

Analyst Price Target is $8.00
▲ +183.69% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ImmunoPrecise Antibodies in the last 3 months. The average price target is $8.00, with a high forecast of $9.00 and a low forecast of $7.00. The average price target represents a 183.69% upside from the last price of $2.82.

This chart shows the closing price for IPA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in ImmunoPrecise Antibodies. This rating has held steady since October 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2023BenchmarkLower TargetSpeculative Buy$12.00 ➝ $7.00Low
3/17/2023HC WainwrightReiterated RatingBuy$9.00Low
12/2/2022HC WainwrightInitiated CoverageBuy$9.00Low
10/25/2021BenchmarkInitiated CoverageBuy$12.00Medium
2/9/2021Industrial Alliance SecuritiesDowngradeBuy ➝ HoldLow
(Data available from 3/30/2018 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

ImmunoPrecise Antibodies logo
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; bi-specific, tri-specific, VHH, and VNAR antibody manufacturing; antibody engineering; and antibody optimization and humanization. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
Read More

Today's Range

Now: $2.82
Low: $2.70
High: $2.90

50 Day Range

MA: $3.98
Low: $2.78
High: $4.90

52 Week Range

Now: $2.82
Low: $2.64
High: $6.50

Volume

44,529 shs

Average Volume

41,671 shs

Market Capitalization

$70.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of ImmunoPrecise Antibodies?

The following Wall Street sell-side analysts have issued research reports on ImmunoPrecise Antibodies in the last twelve months: Benchmark Co., and HC Wainwright.
View the latest analyst ratings for IPA.

What is the current price target for ImmunoPrecise Antibodies?

2 Wall Street analysts have set twelve-month price targets for ImmunoPrecise Antibodies in the last year. Their average twelve-month price target is $8.00, suggesting a possible upside of 183.7%. HC Wainwright has the highest price target set, predicting IPA will reach $9.00 in the next twelve months. Benchmark Co. has the lowest price target set, forecasting a price of $7.00 for ImmunoPrecise Antibodies in the next year.
View the latest price targets for IPA.

What is the current consensus analyst rating for ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IPA will outperform the market and that investors should add to their positions of ImmunoPrecise Antibodies.
View the latest ratings for IPA.

What other companies compete with ImmunoPrecise Antibodies?

Other companies that are similar to ImmunoPrecise Antibodies include Anebulo Pharmaceuticals, GlycoMimetics, Mainz Biomed, Decibel Therapeutics and Adagene. Learn More about companies similar to ImmunoPrecise Antibodies.

How do I contact ImmunoPrecise Antibodies' investor relations team?

The company's listed phone number is 250-483-0308 and its investor relations email address is [email protected] The official website for ImmunoPrecise Antibodies is www.immunoprecise.com. Learn More about contacing ImmunoPrecise Antibodies investor relations.